BDBM129723 US8815926, 2

SMILES: COc1cccc(F)c1-c1nc2C(=O)N(C(c2n1C(C)C)c1ccc(Cl)cc1C)c1cc(Cl)ccc1C

InChI Key: InChIKey=GEUKPOZMDDKKJE-UHFFFAOYSA-N

Data: 3 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 129723   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
MDM2-MDMX (Homo sapiens (Human))	BDBM129723 (US8815926, 2) Show SMILES COc1cccc(F)c1-c1nc2C(=O)N(C(c2n1C(C)C)c1ccc(Cl)cc1C)c1cc(Cl)ccc1C |(4.68,5.6,;3.91,4.26,;4.68,2.93,;6.22,2.93,;6.99,1.6,;6.22,.26,;4.68,.26,;3.91,-1.07,;3.91,1.6,;2.37,1.6,;1.46,2.84,;,2.37,;-1.46,2.84,;-2.23,4.18,;-2.37,1.6,;-1.46,.35,;,.83,;1.46,.35,;1.86,-1.14,;.77,-2.22,;3.35,-1.53,;-1.86,-1.14,;-.77,-2.22,;-1.17,-3.71,;-2.66,-4.11,;-3.06,-5.6,;-3.75,-3.02,;-3.35,-1.53,;-4.44,-.45,;-3.91,1.6,;-4.68,.26,;-6.22,.26,;-6.99,-1.07,;-6.99,1.6,;-6.22,2.93,;-4.68,2.93,;-3.91,4.26,)| Show InChI InChI=1S/C29H26Cl2FN3O2/c1-15(2)34-27-25(33-28(34)24-21(32)7-6-8-23(24)37-5)29(36)35(22-14-19(31)10-9-16(22)3)26(27)20-12-11-18(30)13-17(20)4/h6-15,26H,1-5H3	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	0.170	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe...				US Patent US8815926 (2014) BindingDB Entry DOI: 10.7270/Q29P309G
					More data for this Ligand-Target Pair
MDM2-MDMX (Homo sapiens (Human))	BDBM129723 (US8815926, 2) Show SMILES COc1cccc(F)c1-c1nc2C(=O)N(C(c2n1C(C)C)c1ccc(Cl)cc1C)c1cc(Cl)ccc1C |(4.68,5.6,;3.91,4.26,;4.68,2.93,;6.22,2.93,;6.99,1.6,;6.22,.26,;4.68,.26,;3.91,-1.07,;3.91,1.6,;2.37,1.6,;1.46,2.84,;,2.37,;-1.46,2.84,;-2.23,4.18,;-2.37,1.6,;-1.46,.35,;,.83,;1.46,.35,;1.86,-1.14,;.77,-2.22,;3.35,-1.53,;-1.86,-1.14,;-.77,-2.22,;-1.17,-3.71,;-2.66,-4.11,;-3.06,-5.6,;-3.75,-3.02,;-3.35,-1.53,;-4.44,-.45,;-3.91,1.6,;-4.68,.26,;-6.22,.26,;-6.99,-1.07,;-6.99,1.6,;-6.22,2.93,;-4.68,2.93,;-3.91,4.26,)| Show InChI InChI=1S/C29H26Cl2FN3O2/c1-15(2)34-27-25(33-28(34)24-21(32)7-6-8-23(24)37-5)29(36)35(22-14-19(31)10-9-16(22)3)26(27)20-12-11-18(30)13-17(20)4/h6-15,26H,1-5H3	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.170	n/a	n/a	n/a	n/a	n/a	n/a
Novartis Institutes for BioMedical Research Curated by ChEMBL					Assay Description Inhibition of Cy5-labeled p53 derived TFSDLWKLL peptide binding to C-terminal biotin-labelled human MDM2 (2 to 188 residues) by TR-FRET assay				Bioorg Med Chem Lett 28: 3404-3408 (2018) Article DOI: 10.1016/j.bmcl.2018.08.027 BindingDB Entry DOI: 10.7270/Q2C82D0H
					More data for this Ligand-Target Pair
p53-Binding Protein HDMX (Homo sapiens (Human))	BDBM129723 (US8815926, 2) Show SMILES COc1cccc(F)c1-c1nc2C(=O)N(C(c2n1C(C)C)c1ccc(Cl)cc1C)c1cc(Cl)ccc1C |(4.68,5.6,;3.91,4.26,;4.68,2.93,;6.22,2.93,;6.99,1.6,;6.22,.26,;4.68,.26,;3.91,-1.07,;3.91,1.6,;2.37,1.6,;1.46,2.84,;,2.37,;-1.46,2.84,;-2.23,4.18,;-2.37,1.6,;-1.46,.35,;,.83,;1.46,.35,;1.86,-1.14,;.77,-2.22,;3.35,-1.53,;-1.86,-1.14,;-.77,-2.22,;-1.17,-3.71,;-2.66,-4.11,;-3.06,-5.6,;-3.75,-3.02,;-3.35,-1.53,;-4.44,-.45,;-3.91,1.6,;-4.68,.26,;-6.22,.26,;-6.99,-1.07,;-6.99,1.6,;-6.22,2.93,;-4.68,2.93,;-3.91,4.26,)| Show InChI InChI=1S/C29H26Cl2FN3O2/c1-15(2)34-27-25(33-28(34)24-21(32)7-6-8-23(24)37-5)29(36)35(22-14-19(31)10-9-16(22)3)26(27)20-12-11-18(30)13-17(20)4/h6-15,26H,1-5H3	PDB MMDB NCI pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	411	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe...				US Patent US8815926 (2014) BindingDB Entry DOI: 10.7270/Q29P309G
					More data for this Ligand-Target Pair